Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The white matter (WM) represents approximately half the cerebrum volume and is profoundly affected in Alzheimer’s disease (AD). However, both the WM responses to AD as well as potential influences of this compartment to dementia pathogenesis remain comparatively neglected. Neuroimaging studies have revealed WM alterations are commonly associated with AD and renewed interest in examining the pathologic basis and importance of these changes. In AD subjects, immunohistochemistry and electron microscopy revealed changes in astrocyte morphology and myelin loss as well as up to 30% axonal loss in areas of WM rarefaction when measured against non-demented control (NDC) tissue. Comparative proteomic analyses were performed on pooled samples of periventricular WM (PVWM) obtained from AD (n = 4) and NDC (n = 5) subjects with both groups having a mean age of death of 86 years. All subjects had an apolipoprotein E ε3/3 genotype with the exception of one NDC subject who was ε2/3. Urea-detergent homogenates were analyzed using two different separation techniques: 2-dimensional isoelectric focusing/reverse-phase chromatography and 2-dimensional difference gel electrophoresis (2D-DIGE). Proteins with different expression levels between the 2 diagnostic groups were identified using MALDI-Tof/Tof mass spectrometry. In addition, Western blots were used to quantify proteins of interest in individual AD and NDC cases. Our proteomic studies revealed that when WM protein pools were loaded at equal amounts of total protein for comparative analyses, there were quantitative differences between the 2 groups. Molecules related to cytoskeleton maintenance, calcium metabolism and cellular survival such as glial fibrillary acidic protein, vimentin, tropomyosin, collapsin response mediator protein-2, calmodulin, S100-P, annexin A1, α-internexin, α-and β-synuclein, α-B-crystalline, fascin-1, ubiquitin carboxyl-terminal esterase and thymosine were altered between AD and NDC pools. Our experiments suggest that WM activities become globally impaired during the course of AD with significant morphological, biochemical and functional consequential implications for gray matter function and cognitive deficits. These observations may endorse the hypothesis that WM dysfunction is not only a consequence of AD pathology, but that it may precipitate and/or potentiate AD dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0581-12.2012 · Cited by 128 · cited 1×
“Although the precise functions of these molecules have not been defined it was recently found that α-synuclein is also often elevated in AD (Larson et al., 2012).”
BackgroundRetractedThe basis of anisotropic water diffusion in the nervous system—A technical review.
Beaulieu, C. (2002) · NMR in Biomedicine · doi:10.1002/nbm.782 · Cited by 4,628
Molecular dissection of reactive astrogliosis and glial scar formation
Sofroniew, M. V. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.08.002 · Cited by 2,594 · cited 1×
“A large number of molecular mediators of astrogliosis associated with aging and neurodegenerative disorders (Sofroniew, 2009) have been identified including growth factors, cytokines, Aβ peptides, hypoxia related molecules, reactive oxygen species and glutamate.”
BackgroundAlzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study
Brun, A., & Englund, E. (1986) · Annals of Neurology · doi:10.1002/ana.410190306 · Cited by 1,014
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease
Bartzokis, G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.03.001 · Cited by 968 · cited 1×
“…strengthen the “retrogenesis” hypothesis which proposes that in AD WM degeneration proceeds in a sequence that is the reverse of ontogenic myelinization in the CNS (Stricker et al., 2009; Bartzokis, 2004; Bartzokis, 2011; Braak and Del Tredici, 2004; Choi et al., 2005; Reisberg et al., 1992).”
BackgroundDawson, M. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00210-0 · Cited by 927 · cited 1×
“The decrease of CRMP-2 in AD relative to NDC subjects suggests disturbances in the extension and retraction of cell processes in neurons and oligodendrocytes which are critical for cell migration, axonal contact and myelination (Dawson et al., 2003).”
BackgroundHachinski, V. C., Potter, P., & Merskey, H. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520130013009 · Cited by 755
Review: Cerebral microvascular pathology in ageing and neurodegeneration
Brown, W. R., & Thore, C. R. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01139.x · Cited by 749 · cited 1×
“It has been postulated that loss of proper blood supply to the PVWM is the major cause of “leukoariosis’, since these watershed areas are irrigated by the terminal branches of the deep perforating arteries (reviewed by Brown and Thore (2011)).”
BackgroundTrajectories of cholinergic pathways within the cerebral hemispheres of the human brain
Selden, N. (1998) · Brain · doi:10.1093/brain/121.12.2249 · Cited by 657 · cited 1×
“A possible explanation is the compromise of long association tracts connecting more distant cortical regions and the involvement of cholinergic pathways (Selden et al., 1998).”
BackgroundBozzali, M. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.742 · Cited by 568
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546 · cited 1×
“…strengthen the “retrogenesis” hypothesis which proposes that in AD WM degeneration proceeds in a sequence that is the reverse of ontogenic myelinization in the CNS (Stricker et al., 2009; Bartzokis, 2004; Bartzokis, 2011; Braak and Del Tredici, 2004; Choi et al., 2005; Reisberg et al., 1992).”
BackgroundWilhelmsson, U., Li, L., Pekna, M., Berthold, C.-H., Blom, S., Eliasson, C., Renner, O., Bushong, E., Ellisman, M., Morgan, T. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0820-04.2004 · Cited by 455 · cited 1×
“WM reactive astrogliosis may contribute to the AD neurodegenerative process by inhibiting axonal regeneration (Wilhelmsson et al., 2004; Toyooka et al., 2011).”
BackgroundBraak, H., & Braak, E. (1996) · Acta Neuropathologica · doi:10.1007/s004010050508 · Cited by 406 · cited 1×
“The retrogenesis concept supports the possibility that AD pathogenesis may commence in the WM, rather than in the GM, with oligodendrocyte dysfunction that results in lack of axonal support leading to loss of myelin and alterations in the axonal cytoskeleton (Braak and Braak, 1996).”
BackgroundWhite matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI
Zhang, Y., Schuff, N., Du, A.-T., Rosen, H. J., Kramer, J. H., Gorno-Tempini, M. L., Miller, B. L., & Weiner, M. W. (2009) · Brain · doi:10.1093/brain/awp071 · Cited by 356 · cited 1×
“In AD, fractional anisotropy reductions have been described in a variety of WM regions including the posterior corpus callosum, posterior cingulum, fornix, uncinate, commissural and parahippocampal fibers (reviewed by Zhang et al (2009)).”
BackgroundHistopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging
Scheltens, P., Barkhof, F., Leys, D., Wolters, E. C., Ravid, R., & Kamphorst, W. (1995) · Neurology · doi:10.1212/wnl.45.5.883 · Cited by 344 · cited 1×
“…fibrosis of small vessels, loss of microvessels, interstitial fluid stasis and chronic inflammation (Brun and Englund, 1986; Englund and Brun, 1990; Scheltens et al., 1995; Kalaria, 2002; Bronge et al., 2002; Roher et al., 2003b; Sjobeck et al., 2006; Kalback et al., 2004; Beach et al., 1989;…”
BackgroundGouw, A. A., Seewann, A., Vrenken, H., van der Flier, W. M., Rozemuller, J. M., Barkhof, F., Scheltens, P., & Geurts, J. J. G. (2008) · Brain · doi:10.1093/brain/awn265 · Cited by 281
White matter pathology isolates the hippocampal formation in Alzheimer's disease
Salat, D. H., Tuch, D. S., van der Kouwe, A. J. W., Greve, D. N., Pappu, V., Lee, S. Y., Hevelone, N. D., Zaleta, A. K., Growdon, J. H., Corkin, S., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.013 · Cited by 279
Roher, A. E., Weiss, N., Kokjohn, T. A., Kuo, Y.-M., Kalback, W., Anthony, J., Watson, D., Luehrs, D. C., Sue, L., Walker, D., et al. (2002) · Biochemistry · doi:10.1021/bi026173d · Cited by 279 · cited 2×
“…factors in AD WM. Fibrillar Aβ deposits are capable of activating microglia (Jana et al., 2008) and it remains to be tested whether non-fibrillar Aβ, at the levels found in AD WM, which are ~4-fold of those observed in NDC subjects (Roher et al., 2002), are capable of promoting ANXA1 expression.”
BackgroundSelf-citationProteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain
Korolainen, M. A., Auriola, S., Nyman, T. A., Alafuzoff, I., & Pirttilä, T. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.021 · Cited by 133
O'Dwyer, L., Lamberton, F., Bokde, A. L. W., Ewers, M., Faluyi, Y. O., Tanner, C., Mazoyer, B., O'Neill, D., Bartley, M., Collins, D. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021745 · Cited by 119
Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old
Polvikoski, T. M., van Straaten, E. C. W., Barkhof, F., Sulkava, R., Aronen, H. J., Niinistö, L., Oinas, M., Scheltens, P., Erkinjuntti, T., & Kalaria, R. N. (2010) · Neurology · doi:10.1212/wnl.0b013e318200d6f9 · Cited by 88 · cited 1×
“WMH have also been found to correlate with increased Braak staging and neuritic plaque core densities in AD subjects (Polvikoski et al., 2010).”
Result
Cited by
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460
Self-citationProteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease
Drummond, E., Nayak, S., Faustin, A., Pires, G., Hickman, R. A., Askenazi, M., Cohen, M., Haldiman, T., Kim, C., Han, X., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1691-0 · Cited by 239
Amlien, I. K., & Fjell, A. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.017 · Cited by 219
Myelin changes at the early stage of 5XFAD mice
Gu, L., Wu, D., Tang, X., Qi, X., Li, X., Bai, F., Chen, X., Ren, Q., & Zhang, Z. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.12.013 · Cited by 87
Collins-Praino, L. E., Francis, Y. I., Griffith, E. Y., Wiegman, A. F., Urbach, J., Lawton, A., Honig, L. S., Cortes, E., Vonsattel, J. P. G., Canoll, P. D., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0083-0 · Cited by 79
Metadata
- Authors
- Castao, E. M., Maarouf, C. L., Wu, T., Leal, M. C., Whiteside, C. M., Lue, L.-F., Kokjohn, T. A., Sabbagh, M. N., Beach, T. G., & Roher, A. E.
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 62
- Issue
- 2
- Pages
- 145-156
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W2046254690
- Cited by
- 62
- References
- 24
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.